ArticleChinese journal of integrative medicine2026
Therapeutic Effects of Aqueous Infusion of Cotinus coggygria Scop Leaves on Dextran Sulphate Sodium-Induced Ulcerative Colitis in Mice.
Article in Chinese journal of integrative medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the therapeutic effects of aqueous infusion of Cotinus coggygria Scop. leaves (CCLAI) on the dextran sulphate sodium (DSS)-induced ulcerative colitis (UC) in mice.
methodsA total of 56 C57BL16J mice were divided into 7 groups, including control, DSS model, CCLAI4, CCLAI6, DSS + CCLAI4, DSS + CCLAI6 and DSS + mesalamine groups (n=8). Induction of UC was conducted by 7-day treatment of 3% DSS in mice. CCLAI in 2 different doses (4% and 6%) or mesalamine (250 mg/kg) was administered to C57BL/6J mice orally for 7 consecutive days. The mice in the control group received only tap water. Clinical parameters, antioxidant and anti-inflammatory activities, and histopathological changes in the colon mucosa were examined. Cell proliferatipn index in colon section was determined by immunonistochemical analysis. Colonic cyclooxygenase (COX)-2 and inducible nitric oxide synthase (iNOS) expression levels were detected by Western blot.
resultsCCLAI treatment inhibited DSS-induced colon shortening and significantly improved the Disease Activity Index score (P<0.05 or P<0.01). We also found a significant decrease in myeloperoxidase levels, oxidative stress parameters, and neutrophil infiltration index in the experimental groups receiving CCLAI compared to the control group (all P<0.01). In addition, it was observed that CCLAI administration for 7 days decreased the proinflammatory cytokines levels including interleukin (IL)-1β, IL-6, interferon-γ, and tumor necrosis factor-α in the colon tissues of mice receiving DSS (P<0.05). Further, CCLAI treatment reduced the COX-2 and iNOS levels with an accompanying decrease in prostaglandin E2 and nitric oxide levels, respectively. Additionally, CCLAI treatment markedly decreased the histological lesion score, which was consistent with the reduction of the pro-inflammatory cytokine levels.
conclusionCCLAI treatment significantly improved the DSS-induced UC in mice by diminishing histopathological damage in the colonic mucosa and markedly decreased the inflammatory response through inhibiting the formation of inflammatory cytokines and markers of oxidative stress.
Indexed as
Identifiers
40707806What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.